medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2020, Number 2

Next >>

Arch Neurocien 2020; 25 (2)

Potential sources of bias in the studies of risk and protection factors associated with Parkinson’s Disease

Parra-Medina LE, Álvarez-Cervera FJ, Góngora-Alfaro JL

Language: Spanish
References: 67
Page: 6-18
PDF size: 362.06 Kb.


ABSTRACT

Introduction: Numerous epidemiological studies indicate that Parkinson’s disease (PD) results from a complex interaction between several factors, some of which confer risk and others protection. However, when the methodological design of each study is thoroughly analyzed, it is found that many did not control for various confounding factors, opening the possibility that the identified association (or absence of it) was in fact a methodological artifact.
Objective: To highlight some of the confounding factors that should be controlled to minimize sources of bias in epidemiological studies of risk and protection factors for PD.
Development: A description is made of the possible sources of bias in the studies of factors that have been associated with an increased risk of developing PD (exposure to pesticides, traumatic brain injuries, having relatives in the first and second degree with PD, having suffered from depression, having a history of chronic constipation), as well as factors that seem to confer protection (consumption of tobacco, caffeine and nonsteroidal analgesic drugs).
Conclusions: It is necessary to reach a consensus on the methodology of epidemiological studies of risk/protection factors associated with PD. To reduce bias, the following measures are recommended: apply criteria that increase the certainty that family members with PD were correctly diagnosed, quantitatively estimate the intensity and duration of the factors under study, reduce bias due to reverse causality, excluding from the analysis factors that could occur as a consequence of the prodromal symptoms of PD, which conservatively begin 10 years before diagnosis.


REFERENCES

  1. Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018; 8(s1): S3-S8. DOI: 10.3233/JPD-181474

  2. Przedborski S. The two-century journey of Parkinson disease research. Nat Rev Neurosci 2017; 18(4):251-259. DOI: 10.1038/nrn.2017.25

  3. Caggiu E, Arru G, Hosseini S, Niegowska M, Sechi G, Zarbo IR, et al. Inflammation, infectious triggers, and Parkinson’s disease. Front Neurol 2019; 10: 122. DOI: 10.3389/fneur.2019.00122

  4. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers 2017; 3: 17013. DOI: 10.1038/nrdp.2017.13.

  5. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson’s disease. Ann Neurol 2012; 72(6):893-901. DOI: 10.1002/ana.23687

  6. Martino R, Candundo H, Lieshout PV, Shin S, Crispo JAG, Barakat-Haddad C. Onset and progression factors in Parkinson’s disease: A systematic review. Neurotoxicology 2017; 61: 132-141. DOI: 10.1016/j.neuro.2016.04.003

  7. Chen H. The changing landscape of Parkinson epidemiologic research. J Parkinsons Dis. 2018; 8(1): 1-12. DOI: 10.3233/JPD-171238.

  8. Góngora-Alfaro JL. La cafeína como un fármaco preventivo de la enfermedad de Parkinson: evidencias epidemiológicas y sustrato experimental. Rev Neurol 2010; 50(4): 221-29. DOI: https://doi.org/10.33588/ rn.5004.2009563

  9. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010; 74(12): 995-1002. DOI: 10.1212/WNL.0b013e3181d5a4a3.

  10. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011; 76(10): 863-9. DOI: 10.1212/WNL.0b013e31820f2d79

  11. Bornebroek M, de Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 2007; 28(4): 193-6. https://doi.org/10.1159/000108110

  12. Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord 2008; 23(1): 88-95. DOI: 10.1002/mds.21782

  13. Becker C, Jick SS, Meier CR. NSAID use and risk of Parkinson disease: a population-based case-control study. Eur J Neurol 2011; 18(11): 1336-42. DOI: 10.1111/j.1468-1331.2011.03399.x.

  14. Poly TN, Islam MMR, Yang HC, Li YJ. Non-steroidal antiinflammatory drugs and risk of Parkinson's disease in the elderly population: a meta-analysis. Eur J Clin Pharmacol. 2019; 75(1): 99-108. DOI: 10.1007/s00228-018-2561-y

  15. Ren L, Yi J, Yang J, Li P, Cheng X, Mao P. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis. Medicine (Baltimore). 2018; 97(37): e12172. DOI: 10.1097/MD.0000000000012172

  16. Manterola C, Quiroz G, Salazar P, García N. Metodología de los tipos y diseños de estudio más frecuentemente utilizados en investigación clínica. Rev Med Clin Condes 2019;30(1):36-49. DOI: 10.1016/j.rmclc.2018.11.005

  17. Noordzij M, Hooft L, Dekker FW, Zoccali C, Jager KJ. Systematic reviews and meta-analyses: when they are useful and when to be careful. Kidney Int. 2009;76(11):1130-6. DOI: 10.1038/ki.2009.339

  18. Melamed A, Robinson JN. Case-control studies can be useful but have many limitations: Study design: case-control studies. BJOG. 2019;126(1):23. DOI: 10.1111/1471-0528.15200

  19. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002; 359(9302): 248-52. DOI: 10.1016/S0140-6736(02)07451-2

  20. Van der Mark M, Brouwer M, Kromhout H, Nijssen P, et al. Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ Health Perspect 2012; 120(3): 340-7. DOI: 10.1289/ehp.1103881

  21. Van Maele-Fabry G, Hoet P, Vilain F, Lison D. Occupational exposure to pesticides and Parkinson’s disease: a systematic review and meta-analysis of cohort studies. Environ Int 2012; 46: 30-43. DOI: 10.1016/j.envint.2012.05.004

  22. Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 2013; 80(22): 2035-41. DOI: 10.1212/WNL.0b013e318294b3c8

  23. Ahmed H, Abushouk AI, Gabr M, Negida A, Abdel-Daim MM. Parkinson’s disease and pesticides: A metaanalysis of disease connection and genetic alterations. Biomed Pharmacother 2017; 90: 638-49. DOI: 10.1016/j. biopha.2017.03.100

  24. Gunnarsson LG, Bodin L. Parkinson's disease and occupational exposures: a systematic literature review and meta-analyses. Scand J Work Environ Health. 2017; 43(3): 197-209. DOI: 10.5271/sjweh.3641

  25. Engel LS, Checkoway H, Keifer MC, Seixas NS, Longstreth WT Jr, Scott KC, et al. Parkinsonism and occupational exposure to pesticides. Occup Environ Med 2001; 58(9): 582-9. DOI: 10.1136/oem.58.9.582

  26. Feldman AL, Johansson AL, Nise G, Gatz M, Pedersen NL, Wirdefeldt K. Occupational exposure in parkinsonian disorders: a 43-year prospective cohort study in men. Parkinsonism Relat Disord 2011; 17(9): 677-82. DOI: 10.1016/j.parkreldis.2011.06.009

  27. Ratner MH, Farb DH, Ozer J, Feldman RG, Durso R. Younger age at onset of sporadic Parkinson’s disease among subjects occupationally exposed to metals and pesticides. Interdiscip Toxicol 2014; 7(3): 123-33. DOI: 10.2478/ intox-2014-0017

  28. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009; 169(8): 919-26. DOI: 10.1093/aje/kwp006

  29. Breckenridge CB, Berry C, Chang ET, et al. Association between Parkinson’s disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: systematic review and meta-analysis. PLoS One 2016; 11(4): e015184. https://doi.org/10.1371/journal.pone.0151841.

  30. Nicoletti A, Vasta R, Mostile G, Nicoletti G, Arabia G, Iliceto G, et al. Head trauma and Parkinson’s disease: results from an Italian case-control study. Neurol Sci 2017; 38(10): 1835-39. DOI: 10.1007/s10072-017-3076-5

  31. Baugh CM, Stamm JM, Riley DO, Gavett BE, Shenton ME, Lin A, et al. Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma. Brain Imaging Behav 2012; 6(2): 244-54. DOI: 10.1007/s11682-012-9164-5

  32. Stern RA, Daneshvar DH, Baugh CM, Seichepine DR, Montenigro PH, Riley DO, et al. Clinical presentation of chronic traumatic encephalopathy. Neurology 2013; 81(13): 1122-9. DOI: 10.1212/WNL.0b013e3182a55f7f

  33. Meehan WP, Bachur RG. Sport-related concussion. Pediatrics 2009; 123(1): 114-23. DOI: 10.1542/peds.2008-0309

  34. Rowe BH, Eliyahu L, Lowes J, Gaudet LA, Beach J, Mrazik M, et al., Concussion diagnoses among adults presenting to three Canadian emergency departments: Missed opportunities. Am J Emerg Med. 2018; 36(12): 2144-51. DOI: 10.1016/j.ajem.2018.03.040

  35. Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: A systematic review and metaanalysis. Mov Disord 2013; 28(9): 1222-9. DOI: 10.1002/mds.25458

  36. Crane PK, Gibbons LE, Dams-O’Connor K, Trittschuh E, Leverenz JB, Keene CD, et al. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol 2016; 73(9): 1062-9. DOI: 10.1001/jamaneurol.2016.1948

  37. Lolekha P, Phanthumchinda K, Bhidayasiri R. Prevalence and risk factors of Parkinson’s disease in retired Thai traditional boxers. Mov Disord 2010; 25(12): 1895-901. DOI: 10.1002/mds.23210

  38. Marras C, Hincapié CA, Kristman VL, Cancelliere C, Soklaridis S, Li A, et al. Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 2014; 95(3 Suppl): S238-44. DOI: 10.1016/j.apmr.2013.08.298

  39. Fasano A, Canning CG, Hausdorff JM, Lord S, Rochester L. Falls in Parkinson’s disease: A complex and evolving picture. Mov Disord 2017; 32(11): 1524-36. DOI: 10.1002/mds.27195

  40. Nyström H, Nordström A, Nordström P. Risk of injurious fall and hip fracture up to 26 Y before the diagnosis of Parkinson disease: nested case-control studies in a nationwide cohort. PLoS Med 2016; 13(2): e1001954. https:// doi.org/10.1371/journal.pmed.1001954

  41. Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. A case-control study of occupational and environmental risk factors for Parkinson’s disease in the Emilia-Romagna region of Italy. Neurotoxicology 1998; 19(45): 709-12.

  42. Werneck AL, Alvarenga H. Genetics, drugs and environmental factors in Parkinson’s disease: a case-control study. Arq Neuro Psiquiatr 1999; 57(2B): 347-55. DOI: 10.1590/s0004-282x1999000300001

  43. Rybicki BA, Johnson CC, Peterson EL, Kortsha GX, Gorell JM. A Family History of Parkinson’s disease and its effect on other PD risk factors. Neuroepidemiology 1999; 18(5): 2708. DOI: 10.1159/000026222

  44. Shino MY, McGuire V, Van Den Eeden SK, Tanner CM, Popat R, Leimpeter A, et al. Familial aggregation of Parkinson's disease in a multiethnic community-based case-control study. Mov Disord. 2010; 25(15): 2587-94. DOI: 10.1002/ mds.23361

  45. Marder K, Tang MX, Mejia H, Alfaro B, Côté L, Louis E, et al. Risk of Parkinson’s disease among first-degree relatives: A community-based study. Neurology 1996; 47(1): 155-60. DOI: 10.1212/wnl.47.1.155

  46. Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson’s disease: a case-control study in north-east Italy. Acta Neurol Scand 2002; 105(2): 77-82. DOI: 10.1034/j.1600-0404.2002.1o040.x

  47. Ma C, Liu Y, Neumann S, Gao X. Nicotine from cigarette smoking and diet and Parkinson disease: a review. Transl Neurodegener 2017; 6: 18. DOI: 10.1186/s40035-017-0090-8

  48. Li X, Li W, Liu G, Shen X, Tang Y. Association between cigarette smoking and Parkinson’s disease: A meta-analysis. Arch Gerontol Geriatr 2015; 61(3): 510-6. DOI: 10.1016/j.archger.2015.08.004

  49. Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74(11): 878-84. DOI: 10.1212/WNL.0b013e3181d55f38

  50. Van der Mark M, Nijssen PC, Vlaanderen J, Huss A, Mulleners WM, Sas AM, et al. A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking. PLoS One 2014; 9(4): e95297. DOI: 10.1371/journal.pone.0095297

  51. Hanagiri T, Sugio K, Mizukami M, Ichiki Y, Sugaya M, Yasuda M, et al. Significance of smoking as a postoperative prognostic factor in patients with non-small cell lung cancer. J Thorac Oncol 2008; 3(10): 1127-32. DOI: 10.1097/ JTO.0b013e318186fafb

  52. Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, et al. Smoking, caffeine, and nonsteroidal antiinflammatory drugs in families with Parkinson disease. Arch Neurol 2007; 64(4): 576-80. DOI: 10.1001/ archneur.64.4.576

  53. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernández-Crehuet Navajas R. Smoking and Parkinson’s disease: systematic review of prospective studies. Mov Disord 2004; 19(6): 614-21. DOI: 10.1002/mds.20029

  54. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007; 64(7): 990-7. DOI: 10.1001/archneur.64.7.990

  55. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010; 67(7): 798-801. DOI: 10.1001/archneurol.2010.135

  56. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatr Gerontol Int 2014; 14(2): 430-9. DOI: 10.1111/ggi.12123

  57. Liu R, Guo X, Park Y, Huang X, Sinha R, Freedman ND, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol 2012; 175(11): 1200-7. DOI: 10.1093/aje/kwr451

  58. Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012; 79(7): 651-8. DOI: 10.1212/WNL.0b013e318263570d

  59. Moccia M, Erro R, Picillo M, Vitale C, Longo K, Amboni M, et al. Caffeine consumption and the 4-year progression of de novo Parkinson’s disease. Parkinsonism Relat Disord 2016; 32: 116-19. DOI: 10.1016/j.parkreldis.2016.08.005

  60. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79(4): 36876. DOI: 10.1136/jnnp.2007.131045

  61. Stamey W, Davidson A, Jankovic J. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008; 14(4): 253-4. DOI: 10.1097/RHU.0b013e3181826d43

  62. 62.Walter U, Kleinschmidt S, Rimmele F, Wunderlich C, Gemende I, Benecke R, et al. Potential impact of selfperceived prodromal symptoms on the early diagnosis of Parkinson’s disease. J Neurol 2013; 260(12): 3077-85. DOI: 10.1007/s00415-013-7125-6

  63. Svensson E, Henderson VW, Borghammer P, Horváth-Puhó E, Sørensen HT. Constipation and risk of Parkinson’s disease: A Danish population-based cohort study. Parkinsonism Relat Disord 2016; 28: 18-22. DOI: 10.1016/j. parkreldis.2016.05.016

  64. Wang S, Mao S, Xiang D, Fang C. Association between depression and the subsequent risk of Parkinson’s disease: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2018; 86: 186-92. DOI: 10.1016/j.pnpbp.2018.05.025

  65. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015; 30(12): 1600-11. DOI: 10.1002/mds.26431

  66. Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors. Nat Rev Neurol 2015; 11(11): 625-36. DOI: 10.1038/nrneurol.2015.197

  67. Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T, et al. Reliability of reported age at onset for Parkinson’s disease. Mov Disord 2003; 18(3): 275-9. DOI: 10.1002/mds.10391




2020     |     www.medigraphic.com